The FDA placed a clinical hold on the Phase 2 study of Rocket Pharmaceuticals Inc. on August 11, 2025.
2 reports, 2 independent
Updated Aug 4
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA placed a clinical hold on the Phase 2 study of Rocket Pharmaceuticals Inc. on August 11, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approved the relaunch of Rocket's clinical trial following a previous clinical hold.1 source
FDA placed clinical hold on Rocket Pharma's Phase 2 study.1 source
Keep exploring
The entities involved
Related events
- FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
- FDA issued a partial clinical hold on trials involving Biohaven Ltd. on September 11, 2026.
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
Coverage
Newest first; wire copies grouped- yahoo.com
- prnewswire_rocketClass Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact The Gross Law Firm